Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer

(2016) M. Miyan et al.   Journal of Translational Medicine

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Prenatal maternal stress and wheeze in children: novel insights into epigenetic regulation

(2016) Saskia Trump et al.   Scientific Reports

A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer

(2015) Nicholas C. D'Amato et al.   CANCER RESEARCH

Integrative analysis of 111 reference human epigenomes

(2015) Anshul Kundaje et al.   NATURE

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance

(2015) Nathalie Vigneron et al.   OncoImmunology

Drug-Targeted Inhibition of Peroxisome Proliferator-Activated Receptor-gamma Enhances the Chemopreventive Effect of Anti-Estrogen Therapy

(2015) Hongyan Yuan et al.   Oncotarget

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR

(2015) Ulrike M. Litzenburger et al.   Oncotarget

The UCSC Genome Browser database: 2015 update

(2014) Kate R. Rosenbloom et al.   NUCLEIC ACIDS RESEARCH

IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis

(2014) M. T. Isla Larrain et al.   TUMOR BIOLOGY

Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues

(2014) I. Theate et al.   Cancer Immunology Research

Trial watch: IDO inhibitors in cancer therapy

(2014) Erika Vacchelli et al.   OncoImmunology

Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry

(2013) Hatem Soliman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Model of Tryptophan Metabolism, Readily Scalable Using Tissue-specific Gene Expression Data

(2013) Anne-Kristin Stavrum et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser

(2013) Melissa S. Cline et al.   Scientific Reports

ERα positively regulated DNMT1 expression by binding to the gene promoter region in human breast cancer MCF-7 cells

(2012) Jun-Feng Shi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-γ: Potential therapeutic use in autoimmune diseases

(2012) Zhong-Tian Xue et al.   MOLECULAR IMMUNOLOGY

Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies

(2012) Csaba Juhász et al.   NUCLEAR MEDICINE AND BIOLOGY

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

(2012) L. Pilotte et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development

(2012) Courtney Smith et al.   Cancer Discovery

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence

(2011) M. J. Fackler et al.   CANCER RESEARCH

DNA methylation profiling reveals a predominant immune component in breast cancers

(2011) Sarah Dedeurwaerder et al.   EMBO Molecular Medicine

High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma

(2011) Jocelyne Jacquemier et al.   INTERNATIONAL JOURNAL OF CANCER

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Estrogen and ERα: Culprits in cervical cancer?

(2010) Sang-Hyuk Chung et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Estrogen Receptor Alpha Represses Transcription of Early Target Genes via p300 and CtBP1

(2009) F. Stossi et al.   MOLECULAR AND CELLULAR BIOLOGY